April 8, 2004

INFORMATION DISCLOSURE STATEMENT Patent Application Docket No. GJE-44D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David

William Holden, Jacqueline Elizabeth Shea, Zoe Hindle

Docket No. :

GJE-44D1

For

Attenuated Microorganisms for the Treatment of Infection

Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §§1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/569,601, filed May 9, 2000.

The subject application claims the benefit under 35 USC §120 of the filing date of patent application Serial No. 09/569,601. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/569,601 application, as well as any references cited during the prosecution thereof, be made of record in the subject application. As copies of the references made of record in the 09/569,601 application, and cited on the attached form PTO/SB/08, can be found in the 09/569,601 casefile, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR $\S\S1.97$ and 1.98 are met by the foregoing statements.

Respectfully submitted,

Doran R. Pace

Patient Attorney

Registration No. 38,261

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, FL 32606-6669

DRP/mdp

Attachment: Form PTO/SB/08

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	ubstitute for fon	m 1449A/PTO			Complete if Known		
I IA		TION DICC		DE	Application Number		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	April 8, 2004	
	STATEMENT BY APPLICANT				First Named Inventor	Robert Graham Feldman	
	(us	se as many sheel	ts as nece	ssary)	Art Unit		
					Examiner Name		
	Sheet	1	of	3	Attorney Docket Number	GJE-44D1	

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	U1	US-5,876,931	03-02-1999	Holden	All				
	U2	US-5,643,579	07-01-1997	Hung et al.	All				
	U3	US-							
	U4	US-							
	<u>U5</u>	US-							
	U6	US-							
	U7	US-							
	U8	US-							
	U9	US-							

		FOREIGN	PATENT DOCU	JMENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	Γ
	No. 1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	EPO 0889120 B1	01-07-1999	Microscience Limited	All	
	F2	WO 00/14240	03-16-2000	CREATOGEN BIOSCIENCES GMBH	All	
	F3					1
	F4					
	F5					
	F6					
	F7					

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, osPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 nours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** INFORMATION DISCLOSURE **Filing Date** April 8, 2004 STATEMENT BY APPLICANT **First Named Inventor** Robert Graham Feldman **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet 2 of 3 **Attorney Docket Number** GJE-44D1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	MEDINA, E. et al. "Pathogenicity Island 2 Mutants of Salmonella typhimurium Are Efficient Carriers for Heterologous Antigens and Enable Modulation of Immune Responses", Infection and Immunity, 1999, pp. 1093-1099, Vol. 67, No. 3.	
	R2	VALENTINE, P.J. et al. "Identification of Three Highly Attenuated Salmonella typhimurium Mutants That Are More Immunogenic and Protective in Mice than a Prototypical aroA Mutant", Infection and Immunity, 1998, pp. 3378-3383, Vol. 66, No. 7.	
	R3	HENSEL, M. et al. "Genes Encoding Putative Effector Proteins of the Type III Secretion System of Salmonella Pathogenicity Island 2 are Required for Bacterial Virulence and Proliferation in Macrophages", Molecular Microbiology, 1998, pp. 163-174, Vol. 30, No. 1.	
	R4	HENSEL, M. et al. "Analysis of the Boundaries of Salmonella Pathogenicity Island 2 and the Corresponding Chromosomal Region of Escherichia coli K-12", Journal of Bacteriology, 1997, pp. 1105-1111, Vol. 179, No. 4.	
	R5	HENSEL, M. et al. "Functional Analysis of ssaJ and ssaK/U Operon, 13 Genes Encoding Components of the Type III Secretion Apparatus of Salmonella Pathogenicity Island 2", Molecular Microbiology, 1997, pp. 155-167, Vol. 24, No. 1.	
	R6	SHEA, J.E. et al. "Influence of the Salmonella typhimurium Pathogenicity Island 2 Type III Secretion System on Bacterial Growth in the Mouse", Infection and Immunity, 1999, pp. 213-219, Vol. 67, No. 1.	
	R7	SHEA, J.E. et al. "Identification of a Virulence Locus Encoding a Second Type III Secretion System in Salmonella typhimurium", Proc. Natl. Acad. Sci. USA, 1996, pp. 2593-2597, Vol. 93.	
	R8	CHATFIELD, S. N. et al. "Construction of a Genetically Defined Salmonella typhi Ty2 aroA, aroC Mutant for the Engineering of a Candidate Oral Typhoid-Tetanus Vaccine", Vaccine, 1992, pp. 53-60, Vol. 10, No. 1.	
	R9	LEVINE, M.M. et al. "Attenuated Salmonella as Live Oral Vaccines Against Typhoid Fever and as Live Vectors", Journal of Biotechnology, 1996, pp. 193-196, Vol. 44, No. 1-3.	
	R10	DOUGAN, G. et al. "Live Bacterial Vaccines and Their Application as Carriers for Foreign Antigens", Advances in Veterinary Science and Comparative Medicine, 1989, pp. 277-300, Vol. 33.	
	R11	HOHMANN, E.L. <i>et al.</i> "Evaluation of a phoPl <i>pho</i> Q-deleted, <i>aro</i> A-deleted Live Oral <i>Salmonella typhi</i> Vaccine Strain in Human Volunteers", <i>Vaccine</i> , 1996, pp. 19-24, Vol. 14, No. 1.	
	R12	LOWE, D.C. et al. "Characterization of Candidate Live Oral Salmonella typhi Vaccine Strains Harboring Defined Mutations in aroA, aroC, and htrA", Infection and Immunity, 1999, pp. 700-707, Vol. 67, No. 2.	T
	R13	SCHODEL, F. et al. "Hepatitis B Virus Nucleocapsid/pre-S2 Fusion Proteins Expressed in Attenuated Salmonella for Oral Vaccination", Journal of Immunology, 1990, pp. 4317-4321, Vol. 145, No. 12.	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute	e for form 1449B/F	PTO T		Complete if Known		
	RMATION		CLIDE	Application Number		
	EMENT B			Filing Date	April 8, 2004	
SIAI	CINICIAI D	TAPPLI	CANI	First Named Inventor	Robert Graham Feldman	
(us	e as many shee	ets as necess	an/l	Group Art Unit	- Contract of Contract	
				Examiner Name		
Sheet	3	of	3	Attorney Docket Number	GJE-44D1	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	R14	PLOTKIN, S. A. <u>Vaccines</u> , 1988, p. 571, W.B Saunders Co., Philadelphia.					
	R15						
	R16						
	R17						
	R18						
	R19						
	R20						
	R21						
	R22						
	R23						
	R24						
	R25						
	R26						

Examiner	Date
Cianatura	Date
Signature	Considered
EXAMINER: Initial if reference considered whether	Considered

onsidered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.